Mogrify Appoints Dr Jonathan Appleby as Chief Scientific Officer
15 Julio 2024 - 4:09AM
Business Wire
Strategic hire bolsters executive leadership
team as Company progresses multiple therapeutic programs toward and
into clinical development.
Mogrify Limited (Mogrify®), a regenerative medicine company
developing a novel class of in vivo reprogramming therapies for
diseases with high unmet clinical need, announces the appointment
of Dr Jonathan Appleby as Chief Scientific Officer. With decades of
industry experience in translating both conventional and advanced
therapeutic medicines, Jon will lead advancement of the Company’s
therapeutic programs in areas including otology, ophthalmology and
diabetes toward and into clinical development.
Dr Appleby is an accomplished medicines developer, having
operated in all phases of therapeutic development from discovery to
commercial launch. He joins Mogrify from the Cell and Gene Therapy
Catapult, where he was Executive Director and Chief Scientific
Officer and led the R&D group focused on ATMP manufacturing
processes and analytical development for five years. Prior to this,
Dr Appleby was CSO for Cell and Gene Therapy in GSK’s Rare Diseases
Unit, where he led the team that developed StrimvelisTM, the
multi-award-winning and first autologous pediatric CD34+ stem cell
gene therapy to be approved for commercial use. He also led for 2
years the ARSA gene therapy, which was later out-licensed to
Orchard Therapeutics and recently approved as LenmeldyTM.
Dr Appleby previously held the position of Director and
Portfolio Manager at the GSK Centre of Excellence for External Drug
Development, where he discovered, in-licensed, and developed new
technologies and assets across a broad range of therapeutic areas.
He graduated from the University of Leeds with an honors degree in
Genetics and a PhD from the Department of Biochemistry and
Molecular Biology.
Dr. Darrin M. Disley, OBE, CEO, Mogrify, said: “We are
thrilled to welcome Jon to the Mogrify Executive Team. Following a
comprehensive global search that considered experienced medicine
makers from across the cell and gene therapy paradigm, Jon’s
particular expertise in advancing innovative and first-in-class
medicines for patients with limited treatment options makes him the
ideal candidate for leading Mogrify’s pipeline of novel in vivo
reprogramming therapies through pre-clinical translation and into
first in-human studies.”
Dr. Jon Appleby, Chief Scientific Officer, Mogrify, added:
“Mogrify’s proprietary platform for identifying and optimizing
transcription factor combinations capable of directly reprogramming
cell function in vivo has the potential to address many diseases.
Our multi-talented team has done incredible work in leveraging the
technology to bring forward a portfolio of potentially
transformative medicines. I am delighted to join them as we break
new ground with an approach that combines the potential of both
cell therapy and gene therapy in one novel regenerative
modality.”
For further information about Mogrify’s team, please visit:
https://mogrify.co.uk/team/leadership-team/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240715032498/en/
Lorna Cuddon BSc (Hons) ACIM Tel: +44 (0) 7811 996 942 E-mail:
lorna.cuddon@zymecommunications.com